Showing 421 - 440 results of 27,686 for search '(( 50 ((ms decrease) OR (a decrease)) ) OR ( 50 ((we decrease) OR (mean decrease)) ))', query time: 0.99s Refine Results
  1. 421
  2. 422
  3. 423
  4. 424
  5. 425
  6. 426
  7. 427

    Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  8. 428

    Protocol measures. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  9. 429

    Cry variables. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  10. 430

    Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

    Published 2024
    “…Phosphorylation can reduce toxicity and improve the stability of AMPs. Based on these, we designed a series of peptides and their corresponding phosphorylated forms. …”
  11. 431
  12. 432

    Table_1_Decreased Risk in the Pancreatic Cancer With History of Hay Fever: A Meta-Analysis.doc by Guannan Wang (2209297)

    Published 2020
    “…A history of hay fever was associated with a decreased risk of pancreatic cancer (OR, 0.57; 95% CI, 0.50–0.64, P < 0.00001) through fixed effect model.…”
  13. 433
  14. 434
  15. 435
  16. 436
  17. 437
  18. 438
  19. 439

    Capzb2 coimmunoprecipitates with βIII-tubulin in brain lysates and decreases tubulin polymerization in vitro. by David A. Davis (239142)

    Published 2009
    “…<p>(A) In order to avoid overlap of the heavy chain signal (∼50 kDa) with the βIII-tubulin signal (∼55 kDa) in the immunoprecipitation using the Capzb2 monoclonal antibody (mAb), the antibody was coupled to the protein G/A beads through cross-linking. βIII-tubulin and Capzb2 signals were each detected following immunoprecipitation from brain lysate with both βIII-tubulin rabbit antibody (rAb)-coupled beads and Capzb2 mAb-coupled beads. …”
  20. 440